Baird Maintains Outperform on Exact Sciences, Lowers Price Target to $67
EXASNovember 6, 2024
Read more →Exact Sciences Stock Plummets After Worse-Than-Expected Q3 Results, FY24 Guidance Below Estimates
EXASExact Sciences shares are dropping after the company reported its third-quarter results after Tuesday's closing bell. Here's a look at the details.
November 5, 2024
Read more →Exact Sciences Sees FY24 Total Revenue $2.730B-$2.750B Vs $2.832B Est.
EXASNovember 5, 2024
Read more →Exact Sciences Q3 2024 GAAP EPS $(0.21) Misses $(0.20) Estimate, Sales $709.00M Miss $717.66M Estimate
EXASNovember 5, 2024
Read more →Exact Sciences Announced That A District Court Judge Denied In Part Geneoscopy's (Defendant) Motion To Dismiss A Patent Infringement Lawsuit Filed By Exact Sciences (Plaintiff) In The United States District Court For The District Of Delaware
EXASMay 21, 2024
Read more →Exact Sciences Option Alert: May 20 $58 Calls Sweep (38) near the Ask: 285 @ $4.0 vs 0 OI; Ref=$57.77
EXASApril 28, 2022
Read more →Exact Sciences's Return On Capital Employed Insights
EXASAccording to data from Benzinga Pro, during Q1, Exact Sciences's (NASDAQ:EXAS) reported sales totaled $486.57 million. Despite a 17.98% increase in earnings, the company posted a loss of $180.94 million.
April 28, 2022
Read more →Exact Sciences Highlights Updated, Expanded American Society Of Clinical Oncology Guidelines That Recommend Use Of Co.'s Oncotype Breast Recurrence Score Test
EXASApril 28, 2022
Read more →